Cellectar Biosciences, Inc.

Healthcare · Biotechnology · United States

Last price 1.22 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.53M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 cli...